loading...
Tampilkan postingan dengan label Antispasmodics. Tampilkan semua postingan
Tampilkan postingan dengan label Antispasmodics. Tampilkan semua postingan

Gitas Injeksi

13:00 Add Comment
Gitas Injeksi
GITAS®
INJEKSI

KOMPOSISI:
Tiap ml mengandung :
Hyoscine N-butylbromide ........................ 20 mg

KHASIAT:
GITAS® Injeksi mengandung Hyoscine N-butylbromide mempunyai efek antimuskarinik yang bekerja pada saraf serabut pasca ganglion kolinergik, juga mempunyai efek antispasmodik pada traktus gastrointestinal, traktus biliaris dan traktus urinarius.
Mempunyai mula kerja 30 menit dengan lama kerja 4 jam, diekskresikan melalui ginjal dalam bentuk tak berubah.

INDIKASI:
GITAS® Injeksi diindikasikan untuk kejang akut seperti kolik ginjal atau empedu.
Pada radiologi, digunakan untuk diagnosa differensial pada obstruksi dan mengurangi kejang dan sakit pada pyelografi, dan untuk prosedur diagnostik yang lain dimana terjadi kejang yang menjadi problem seperti endoskopi pada gastroduodenal.


KONTRA INDIKASI:
  • Porfiria.
  • Jangan diberikan pada pasien dengan penyakit-penyakit glaukoma, hipertrofi prostat dengan kecenderungan retensi urine, stenosis mekanis di daerah traktus gastrointestinal, takikardia, megakolon.
  • Penderita yang hipersensitif terhadap komponen tersebut diatas.


EFEK SAMPING:
Kekeringan pada mulut dan kulit, konstipasi, palpitasi, "flushing", aritmia jantung, bradikardia dan takikardia.
Pernah dilaporkan menyebabkan reaksi paradoxikal (gangguan waktu tidur) dan mempengaruhi penglihatan, oleh sebab itu hali-hati dalam mengemudikan kendaraan bermotor atau menjalankan mesin.


PERINGATAN / PERHATIAN:
  • Penggunaan pada wanita hamil hanya direkomendasikan jika benar-benar dibutuhkan terutama pada trimester 1 kehamilan dengan mempertimbangkan resikonya terhadap janin.
  • Keamanan pada wanita menyusui belum dapat dibuktikan.
  • Hati-hati penggunaan pada pasien lanjut usia, pasien dengan gangguan jantung, kolitis ulseratif, paralytic ileus dan pyloric stenosis.
  • Hindari mengkonsumsi minuman beralkohol.

INTERAKSI OBAT:
  • Pemberian bersama dengan CNS depresant dapat memperkuat efek antikolinergik GITAS® Injeksi.
  • Pemberian bersama lorazepam meningkatkan sedasi halusinasi.

ATURAN PAKAI:
Injeksi:
1 ampul (i.m. atau i.v.) diulang setelah ½ jam jika perlu.
Jika digunakan untuk endoskopi, dosis ini dapat diulang lebih sering.

KEMASAN:
Kotak berisi 5 ampul a 1 ml
No. Reg. : DKL9817614643A1

HARUS DENGAN RESEP DOKTER

SIMPAN DITEMPAT SEJUK DAN KERING 
TERHINDAR DARI CAHAYA

Diproduksi oleh :
PT. Interbat
Jl. H.R.M. Mangundiprojo no. 1
Buduran, Sidoarjo-61252
Jawa Timur, Indonesia

Epidosin Injeksi

11:00 Add Comment
Epidosin Injeksi
Epidosin
Valethamate Bromide
Antispasmodik

KOMPOSISI
Tiap ampul @ 1 ml mengandung : Valethamate Bromide 8 mg

CARA KERJA
Efek postganglionik seperti yang dimiliki atropin merupakan sifat farmakologi terpenting dari Valethamate. Valethamate memiliki efek langsung pada otot polos.

INDIKASI
Spasme saluran cerna (spasme pada sfinger kardia, spasme karena sembelit, tukak lambung dan usus dua belas jari), spasme ringan sampai sedang pada saluran empedu dan saluran kemih, dismenore spastik, terlambatnya dilates serviks pada waktu partus.
Pediatri: spasme pada pylorus, bronchitis spastik, emesis astonemik.

KONTRA INDIKASI
Hipersensitivitas terhadap obat ini.

INTERAKSI OBAT
Efek obat meningkat pada penggunaan secara bersamaan dengan obat yang bersifat antimuscarinik (seperti amantadine) beberapa antihistamin, anti psikolik fenotiazine dan anti depresi trisiklik.

EFEK SAMPING
Mulut kering, reduksi sekresi bronchial, dilatasi pupil (midriasis) dengan kehilangan daya akomodasi dan photophobia, kulit kering dan merah, bradycardia sementara yang diikuti tachycardia, konstipasi.

PERINGATAN DAN PERHATIAN
  • Hati-hati pemberian pada pasien dengan tachycardia seperti thyrotoxicosis, gagal jantung dan pada pembedahan jantung karena dapat mempercepat denyut jantung.
  • Pada pasien dengan acute myocardial infaction dan ischaemia karena kondisi penyakit akan memburuk pada pasien dengan hipertensi.

DOSIS
Menurut petunjuk dokter, umumnya:
Ampul @ 1 ml :
i.v., i.m. atau s.k., sehari 1 - 2 ampul. Apabila periu suntikan dapat diulang

KEMASAN
Dus, berisi 10 ampul @ 1 ml (No. Reg. DKL7812424043A1)

HARUS DENGAN RESEP DOKTER

Catatan :
Ampul dapat langsung dibuka tanpa menggunakan pembuka ampul.
Simpan pada suhu kamar (25 - 30°C), serta terlindung dari cahaya.

PT. KIMIA FARMA
JAKARTA-INDONESIA

Spasmium

06:00 Add Comment
Spasmium
SPASMIUM®

KOMPOSISI:
Tiap dragee mengandung:
Chlordiazepokside HCl ..... 5 mg
Phenylpropylethylamine ..... 30 mg

FARMAKOLOGI:
Spasmium® merupakan suatu kombinasi antispasmodik dan tranquilizer sehingga dapat menstabilkan fungsi viceromotor dengan cepat dengan cara menghilangkan hipermotilitas atau kejang dan sekaligus menghilangkan faktor-faktor emosional yang seringkali menjadi penyebab utamanya.

INDIKASI:
Gangguan-gangguan saluran cerna dan sistem urogenital seperti hipermotilitas, kejang saluran kemih dan rahim.

TAKARAN PEMAKAIAN :
Sehari 3 kali 1-2 dragee menurut umur, indikasi dan keadaan penderita. Untuk penderita yang lanjut usia dan penderita yang lemah diberikan takaran yang lebih kecil, yang dapat dinaikkan sampai takaran paling efektif yang dapat ditolerir dengan baik.

PERINGATAN DAN PERHATIAN :
Karena mengandung Chlordiazepokside HCl, Spasmium® dapat menyebabkan mengantuk pada penderita lanjut usia dan penderita yang lemah, tetapi pengaruh ini dapat dihindari dengan menyesuaikan takaran pemakaian yang tepat.
Selama penggunaan Spasmium®, hindari minum alkohol dan mengerjakan pekerjaan yang membutuhkan lebih banyak konsentrasi (misalnya mengemudi) harus berhati-hati, karena Chlordiazepokside HCl dapat mengurangi reaksi penderita.
Hindari pemakaian pada wanita hamil terutama trimester pertama. Penggunaan jangka lama dapat menyebabkan ketergantungan fisik atau psikis. Hati-hati bila diberikan pada penderita dengan gangguan hati dan ginjal.

EFEK SAMPING :
Perasaan lelah, pusing dan mengantuk.

KONTRA INDIKASI:
Penderita yang hipersensitif.

KEMASAN:
- Botol @ 200 dragee DPL 7224207216A1
- Box, 10 strip @ 10 dragee D2015874-I

HARUS DENGAN RESEP DOKTER

SIMPAN DI BAWAH SUHU 30°C
TERLINDUNG DARI CAHAYA

PT SOHO INDUSTRI PHARMASI
Jl. Pulogadung No. 6
JAKARTA - INDONESIA

Buscopan Tablet

00:14 Add Comment
Buscopan Tablet
Buscopan® Tablet
Hyoscine-N-butylbromide

Composition
1 sugar-coated tablet contains: Hyoscine-N-butylbromide 10 mg

Properties
BUSCOPAN exerts a spasmolytic action on the smooth muscle of the gastrointestinal, biliary and genitourinary tracts. As a quarternary ammonium derivative, Hyoscine-N-butylbromide does not enter the central nervous system. Therefore, anti-cholinergic side effects at the central nervous system do not occur. Peripheral anti-cholinergic action results from a ganglion-blocking action within the visceral wall as well as from an anti-muscarinic activity.


Indications
Gastrointestinal tract spasm, spasm and dyskinesia of the biliary system, genitourinary tract spasm


Contraindications
BUSCOPAN is contraindicated in myasthenia gravis and megacolon. In addition, it should not be used in patients who have demonstrated prior sensitivity to hyoscine-N-butylbromide or any other component of the product.
  • Urinary retention associated with mechanical stenosis of the urinary tract (e.g. in the case of prostatic adenoma)
  • Narrow angle glaucoma
  • Tachycardia
Side Effects
Anti-cholinergic side effects including xerostomia, dyshidrosis, tachycardia and potentially urinary retention may occur but are generally mild and self limited. Very rarely hypersensitivity reactions, particularly skin reactions have been reported. Isolated cases of anaphylaxis with episodes of dyspnoea and shock have been observed.


Special Precautions
Because of the potential risk of anti-cholinergic complications, caution should be used in patients prone to narrow angle glaucoma as well as in patients susceptible to intestinal or urinary outlet obstructions and in those inclined to tachyarrhytmia. Because of the possibility that anti-cholinergic may reduce sweating. BUSCOPAN should be administered with cautions to patients with pyrexia and in situations where the ambient temperature is high.


Pregnancy and Lactation
Long experience has shown no evidence of ill-effects during human pregnancy. Preclinical studies in rats and rabbits did not show either embryo-toxic or teratogenic effects. However the usual precautions regarding the use of drugs in pregnancy, especially during the first trimester, should be observed.
Safety during lactation has not yet been established.


Drug Interactions
The anti-cholinergic effect of tricyclic antidepressants, antihistamines, quinidine, amantadine, phenothiazines, butyrophenons and disopyramide may be intensified by BUSCOPAN.
Concomitant treatment with dopamine antagonists such as metoclopramide may result in diminution of the effects of both drugs on the gastrointestinal tract
The tachycardic effects of beta-adrenergic agents may be enhanced by BUSCOPAN.


Dosage and Administration
Unless otherwise prescribed by the physician, the following dosages are recommended:
Oral
Sugar-coated tablets:
Adults and children over 6 years: 4 times daily 1-2 s.c. tablets.
The sugar-coated tablets should be swallowed whole with adequate fluid.

Over dosage
Symptoms
In the cases of over dosage, anti-cholinergic effects may be observed.

Therapy
If required, parasympathomimetic drugs should be administered. Ophthalmological advice should be shought in cases of glaucoma urgently.
Cardiovascular complications should be treated according to usual therapeutic principles. In case of respiratory paralysis: intubation, artificial respiration should be considered. Catheterization may be required for urinary retention. In addition, appropriate supportive measures should be used as required.

Availability
Sugar-coated tablets Reg. No. DKL0133700U6A1
Box contains 10 strips of 10 tablets-

Store in 25-30° C, protect from light. Store in a safe place, out of the reach of children.

Only on doctor's prescriptions

Harus dengan resep dokter

Manufactured by:
PT. Boehringer lngelheim Indonesia
Bogor, Indonesia

Under license from:
Boehringer Ingelheim International GmbH
Ingelheim am Rhein
Germany

Librax

15:05 Add Comment
Librax
Librax®
Chlordiazepoxide + clidinium bromide

As adjunctive therapy in the treatment of peptic ulcer and irritable bowel syndrome

Composition
Each dragee contains: 5 mg Chlordiazepoxide (7-Chloro-2-methylamino-5-phenyl-3H-1,4benzodiazepine-4-oxide) and 2.5 mg Clidinium bromide (3-Benziloyloxy-l-
methylquinuclidinium bromide). 1 dragee contains 279 mg carbohydrate (4.6 kJ).

Mode of Action
Chlordiazepoxide has antianxiety, sedative, appetite stimulating and weak analgesic actions. The precise mechanism of action is not known. The drug bloks EEG arousal from stimulation of the brain stem reticular formation. It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours. After the drug is discontinued plasma levels decline slowly over a period of several days. Chlordiazepoxide is excreted in the urine with 1 % to 2 % unchanged and 3% to 6% as a conjugate.
Clidinium (other synthetic quaternary ammonium compounds), is ionized and rarely
affect the central nervous system because they do not readily cross the blood-brain
barrier. Their ionization is largely responsible for the wide individual variability in
absorption noted after oral administration. Most of their actions are attributable to the
antimuscarinic effect of usual therapeutic doses. Some antispasmodic actions of
quaternary ammonium compounds may be due to their relatively specific ganglionic
blocking effects in the gastrointestinal tract.

Indications
As adjunctive therapy in the treatment of peptic ulcer and irritable bowel syndrome

Dosage
Usual adult dose:
Oral, 1 or 2 dragees one to four times a day, thirty to sixty minutes before meals or food, the dosage then being adjusted as needed and tolerated.

Usual geriatric dose:
Oral, initially no more than 1 dragee two times a day, the dosage then being adjusted as needed and tolerated.

Usual pediatric dose:
Dosage has not been established.

Contraindications
Librax is contraindicated for patients with known hypersensitivity to Chlordiazepoxide or clidinium bromide, and also in the presence of glaucoma.
Patients with reflux esophagitis because Librax decrease both esophageal and gastric motility and relax the lower esophageal sphincter.

Warnings and Precautions
Particular caution is advised in patients with prostatic hypertrophy or myasthenia gravis.
Depending on dosage, administration and individual susceptibility, Librax may modify the patient's reactions (e.g. driving ability, behavior in traffic). Blood, renal and hepatic function tests are recommended if treatment is given for prolonged periods.

Dependence
The use of benzodiazepines and benzodiazepine-like agents may lead to the development of physical and psychic dependence. The risk of dependence increases with dose and duration of treatment; it is also greater in patients with a history of alcohol or drug abuse.
Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms. These may consists of headaches, muscle pain, extreme anxiety, tension, restlessness, confusion and irritability. In severe cases, the following symptoms may occur: derealization, depersonalization, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations or epileptic seizures.
Since the risk of withdrawal phenomena and rebound phenomena is greater after abrupt discontinuation of treatment, it is recommended that the dosage be decreased gradually.

Pregnancy, nursing mothers
For fundamental medical reasons, Librax should not be administered in early pregnancy unless it is considered imperative to do so.
Chlordiazepoxide and clidinium bromide pass into the milk of nursing mothers.

Over dosage
Measures recommended for accidental or deliberate over dosage are gastric lavage, maintenance of airway patency and surveillance of the patient. If symptoms attributable to chlordiazepoxide predominate, flumazenil is indicated.
The usual precautions in treating patients with impaired renal or hepatic function should be observed.
To assure the safe and effective use of benzodiazepines, patients should be informed that since Librax may produce psychological and physical dependence it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.
Since antacids may interfere with absorption of antichlolinergic agents, these drugs should not be given concomitantly, at interval of at least one hours is suggested.

Side effects
  • Side effects such as dryness of the mouth, constipation and disorders of micturition may occasionally occur. In elderly patients slight drowsiness may sometimes be observed, especially at the beginning of treatment. This usually disappears spontaneously or in response to a dosage reduction.
  • Agranulocytosis, granulocytopenia or leukopenia, allergic reactions.
    In a few instances syncope has been reported.
  • Other adverse reaction reported during therapy include isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea, constipation, extra pyramidal symptoms, as well as increased and decreased libido. Such side effects have been infrequent and are generally controlled with reduction of dosage.
Interactions
If Librax is taken concurrently with preparations containing anticholinergic ingredients, e.g. amantadine, various antihistamines, butyrophenones, phenotiazines, tricyclic and tetracyclic antidepressants, the anticholinergic action of clidinium bromide is potentiated.
During treatment with Librax, patients should avoid alcohol since the individual response can not be foreseen.

Stability
This medicine should not be used after the expiry date shown on the pack.

Packaging
Box, 10 strips of 10 dragees Reg.No. DPL0004126716A1

Store at room temperature
Keep all medicine out of the reach of children

On medical prescription only
Harus dengan resep dokter

Manufactured by:
PT. COMBIPHAR, Bandung-Indonesia

Under licence from:
ICN Pharmaceuticals, Inc.
Costa Mesa, California-USA
loading...